iTeos Therapeutics (ITOS) Competitors

Wave Life Sciences (NASDAQ:WVE) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.

Does the media prefer WVE or ITOS?

In the previous week, Wave Life Sciences had 5 more articles in the media than iTeos Therapeutics. MarketBeat recorded 15 mentions for Wave Life Sciences and 10 mentions for iTeos Therapeutics. Wave Life Sciences' average media sentiment score of 1.00 beat iTeos Therapeutics' score of 0.74 indicating that Wave Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Wave Life Sciences	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
iTeos Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, WVE or ITOS?

Wave Life Sciences has higher revenue and earnings than iTeos Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wave Life Sciences	$108.30M	10.90	-$57.51M	-$0.79	-9.73
iTeos Therapeutics	$35M	8.10	-$112.64M	-$3.31	-2.24

Is WVE or ITOS more profitable?

iTeos Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. iTeos Therapeutics' return on equity of -20.11% beat Wave Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Wave Life Sciences	-66.50%	-280.57%	-52.90%
iTeos Therapeutics	N/A	-20.11%	-17.50%

Which has more risk and volatility, WVE or ITOS?

Wave Life Sciences has a beta of -0.93, suggesting that its stock price is 193% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Do insiders & institutionals believe in WVE or ITOS?

89.7% of Wave Life Sciences shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 29.1% of Wave Life Sciences shares are held by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer WVE or ITOS?

Wave Life Sciences received 321 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 81.03% of users gave iTeos Therapeutics an outperform vote while only 67.90% of users gave Wave Life Sciences an outperform vote.

Company	Underperform	Outperform
Wave Life Sciences	Outperform Votes 368 67.90%	Underperform Votes 174 32.10%
iTeos Therapeutics	Outperform Votes 47 81.03%	Underperform Votes 11 18.97%

Do analysts rate WVE or ITOS?

Wave Life Sciences currently has a consensus price target of $21.17, suggesting a potential upside of 175.32%. iTeos Therapeutics has a consensus price target of $25.50, suggesting a potential upside of 243.48%. Given iTeos Therapeutics' higher probable upside, analysts clearly believe iTeos Therapeutics is more favorable than Wave Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wave Life Sciences	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.00
iTeos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Wave Life Sciences beats iTeos Therapeutics on 10 of the 18 factors compared between the two stocks.